Knockdown of Long Non-coding RNA SNGH3 by CRISPR-dCas9 Inhibits the Progression of Bladder Cancer

Yu Cao†1, Qiong Hu†1, Ruiming Zhang†1, Ling Li‡1, Mingjuan Guo3, Huiling Wei3, Li Zhang3*, Kai Yang, Zhejiang University, China

†Correspondence: Li Zhang
fsfyli@sina.com
Jianfeng Wang
jianfeng1977@aliyun.com
Chunjing Li
164194249@qq.com

†These authors have contributed equally to this work

Recent research evidence documents that IncRNAs (long non-coding RNAs IncRNAs) play a pivotal role in the tumorigenesis and development of tumors. LncRNA SNGH3 (small nucleolar RNA host gene 3) is highly expressed in numerous forms of cancer, serving as an oncogene in cancer progression. Nonetheless, the clinical relationship, along with the mechanism of SNGH3 in bladder cancer, have not been studied. Herein, the findings exhibited upregulation of SNGH3 in bladder cancer tissues, along with the cell lines. Furthermore, overexpressed SNGH3 was positively linked to the TNM stage, as well as the histological grade of bladder cancer. Moreover, the silencing of SNGH3, using CRISPR-dCas9, suppressed cell growth along with migration, but elevated bladder cancer cell apoptosis. In summary, we established that SNGH3 serves as a bladder cancer oncogene and could be employed as a prospective diagnostic marker for clinical use, and is also a therapeutic target for CRISPR-mediated gene therapy.

Keywords: SNGH3, bladder cancer, CRISPR-dCas9, IncRNA, therapeutic target

INTRODUCTION

Human bladder cancer, which has high incidence and a high mortality, is the most frequent type of the urinary system tumors. According to statistics, there are approximately 549,000 new cases of bladder cancer and 200,000 people died of the disease in 2018 (Bray et al., 2018). Although significant advancements have been made in the treatment of bladder cancer in recent years, the 5 year survival rate and prognosis of patients with advanced bladder cancer remain low (Kamat et al., 2016; Dy et al., 2017; Massari et al., 2018). Early diagnosis and treatment of bladder cancer is strongly linked to the prognosis of patients. Frequent relapse along with distant metastasis of bladder cancer are the primary causes of treatment failure. However, the exact molecular biology of bladder cancer remains unknown. Therefore, it is critical to find new effective biological targets for the diagnosis, as well as the treatment of bladder cancer.

Long non-coding RNA (IncRNA) is a non-coding RNA molecule with a length of more than 200 nt. Because IncRNAs lack (ORFs) open reading frames, they cannot be translated into proteins (Ponting et al., 2009). Recent research findings have documented that IncRNAs have a core role in
cell proliferation, apoptosis, infiltration, and other biological processes, as well as gene regulation, chromatin remodeling, and other molecular levels (Tsai et al., 2010; Quinodoz and Guttman, 2014). In addition, a large number of IncRNAs participate in tumor development along with metastasis (Huarte, 2015). The expression characteristics of IncRNAs have obvious tissue or cell specificity. They can be used as oncogenic factors or tumor repressors (Evans et al., 2016; Chen Y. et al., 2017). In many classical instances, IncRNAs are employed as guides or molecular scaffolds that modulate protein-protein or DNA-protein cross talks, as enhancers that modulate transcription, or as miRNA (microRNA) sponges to adsorb miRNAs (Jandura and Krause, 2017; Marchese et al., 2017). IncRNA can also be used as readouts of active cellular genetic programs or conductors of distinct cellular signaling events, can assess the pathological state of cancers, and offers prognostic ability for cancer patients (Engreitz et al., 2016). For example, IncRNA MALAT-1 has been found to be upregulated in various malignant tumors, and upregulated MALAT-1 is remarkably linked to worse OS (overall survival) or DFS (disease-free survival) in individuals with gastrointestinal carcinomas (Chen D. et al., 2017; Wu et al., 2018). High expression of IncRNA HOXA1 in primary, as well as metastatic breast cancer indicates dismal prognosis. It promotes the infiltration along with the metastasis of breast cancer cells by mediating PRC2 relocation and modulating H3K27 methylation (Milevskiy et al., 2016; Portoso et al., 2017). LncRNA-HOXD-A51 functions as a sponge of miRNA and competitively bind with miR-130a, thereby upregulating the expression of the EF28 transcription factor, and enhancing the migration and infiltration of glioma cells (Chen et al., 2018). Therefore, it is extremely necessary to conduct a comprehensive genomic and cellular functional study on the changes of IncRNA in tumor development along with metastasis, which will help to uncover new cancer diagnosis and treatment targets.

The dysregulation of IncRNAs is closely linked to multiple cancer types, such as small nucleolar RNA host gene (SNHG) related IncRNA. Recently, accumulating evidence suggests that small nucleolar RNA host genes of IncRNAs participate in the onset of cancer, accelerating the progression of cancer cells. For instance, IncRNA SNHG1 promotes the growth of colon and lung cancer by enhancing the transcriptional level of neighboring gene SLC3A2 and accelerating the phosphorylation of the PI3K/Akt pathway (Sun et al., 2017). The oncogenic IncRNA, SNHG6 enhances genomic hypomethylation by inhibiting the generation of SAmE. Moreover, SNHG6 sponges miR-1297 to increase MAT2A expression, upregulating MAT2A expression in hepatocellular carcinoma (Guo et al., 2018). Shan et al. (2018) documented that IncRNA SNHG7 was highly expressed in colorectal cancer and increased up regulated SNHG7 expression, promoted the cell growth and migration by acting as the miR-216b sponge to affect the expression and GALNT1 and EMT markers.

To the best of our knowledge, there is no study showing the biological function of IncRNA SNHG3 in bladder cancer. Herein, the data revealed IncRNA SNHG3 upregulation in bladder cancer tissues, as well as cell lines in contrast with the matched bladder non-malignant tissues and SV-HUC1 cells, respectively. Elevated SNHG3 expression was positively linked to the TNM stage along with the histological grade of individuals with bladder cancer. In addition, upregulated SNHG3 expression was shown to result in the dismal prognosis of bladder cancer patients, causing lower OS and DFS. Further functional assays illustrated that SNHG3 silencing, by CRISPR-dCas9, repressed the bladder cancer cell growth, as well as migration and enhanced cell apoptosis.

**MATERIALS AND METHODS**

**Patient Samples**

Overall, 41 individuals who were diagnosed with bladder cancer and who had undergone partial or radical cystectomy at the Affiliated Foshan Maternal and Child Healthcare Hospital were enrolled in the study. All the bladder cancer tissues along with the matching neighboring non-malignant tissues were stored in RNA later and then immediately snap-frozen in liquid nitrogen.

All subjects who enrolled in the present study approved this research and provided written informed consent. In addition, we performed the study with the approval of the Research Ethics Committee of the Affiliated Foshan Maternal and Child Healthcare Hospital.

**Cell Culture**

The 5637, SW780, and T24 human bladder cancer cells along with the SV-HUC-1 human non-malignant bladder epithelial cells were all supplied by ATCC. The RPMI-1640 Medium (Gibco) augmented with 10% FBS (Invitrogen, Carlsbad, CA, United States) was utilized to grow all the cells under 37°C and 5% CO2 growth conditions.

**Cell Transfection**

SW780 along with the 5637 cells were transiently inserted with specific sgRNA targeting on IncRNA SNHG3 through transfection. The SNHG3 sgRNA sequence was listed as follows: sgRNA-1: 5′-GGACTTCCGGGACCTTCTGTA-3′; sgRNA-2: 5′-GGACTTCCGGGACCTTCTGTA-3′; sgRNA-3: 5′-GATGCTTGCACCAGGAGTGT-3′. SNHG3 sgRNA (sg-SNHG3), and the sg-NC (negative control) were synthesized by GenePharma (Suzhou, China). The Lipofectamine 3000 (Invitrogen, Carlsbad, CA) was employed to transfect the bladder cancer cells as described by the manufacturer. Transfection was done after the cultured cells attained 50–70% confluence in six-well plates. We harvested the transfected cells for real-time quantitative PCR after 48 h.

**RT-qPCR**

The Trizol reagent (Invitrogen, Carlsbad, CA, United States) was utilized to isolate total RNA from the bladder cancer tissues and cells as described in the manual provided by the manufacturer. After that, cDNA was processed from 1 µg total RNA with the PrimeScript RT Reagent Kit with gDNA Eraser (Takara, Dalian, China) via reverse transcription. Subsequently, 2 µl of cDNA was employed as the template in qPCR process consisting of 10 µl of SYBR Green PCR kit mix (Takara, Dalian, China), 0.5 µl specific forward primer, 0.5 µl specific reverse primer, and 7 µl
of deionized water. This assay was carried out and analyzed on the ABI7000 system (Applied Biosystems, Foster City, CA, United States). The GAPDH gene served as the internal standard. Each sample was assayed in triplicate.

**Cell Proliferation Assessment**

The CCK along with the MTT assays were employed to study cell proliferation. At 48 h after transfection with sg-SNHG3 or sg-NC, we harvested the cells and then inoculated them in a 96-well plate for 24 h. Afterward, 10 µl CCK-8 reagent was introduced to every well at intervals of 0, 24, 48, and 72 h post cell attachment. The cells were cultured in darkness for 1 h. Next, a micro-plate reader (Bio-Rad, Hercules, CA, United States) was employed to determine the OD values at 450 nm. The MTT assay was employed to validate the CCK-8 assay data. In brief, we introduced 10 µl of MTT reagent to every well at 0, 24, 48, and 72 h post cell attachment. The cells were cultured in darkness for 1 h and then 100 µl of DMSO was introduced. A micro-plate reader (Bio-Rad, Hercules, CA, United States) was employed to determine the OD values at 450 nm after 10 min of vibration.

**Cell Migration Assessment**

Cell migration was explored by the scratch assay and transwell assay. The bladder cancer cells were inserted with specified sgRNA oligonucleotides when cells attained 90% confluence. At 24 h after transfection, we used a sterile 200 µl pipette tip to

---

**FIGURE 1**

SNGH3 was highly expressed in bladder cancer tissues, and cell lines. (A) 41 bladder cancer samples were analyzed herein. SNHG3 was highly expressed in 28 of 41 bladder cancer tissue samples. (B) Total SNHG3 expression in bladder cancer tissue was remarkably higher in contrast with that in matched neighboring non-malignant tissues. (C) SNHG3 RNA content was higher in T2-T4 stage cancers in contrast with those in Ta-T1 cancers. (D) SNHG3 RNA content was higher in high grade cancers in contrast with those in low grade cancers. (E) The association of SNHG3 content with OS. (F) The association of SNHG3 RNA content with DFS. (G) SNHG3 was overexpressed in SW780 and 5637 cells in contrast with that in SV-HUC1. Data were indicated as means ± SD from three independent experiments (**P < 0.01).
generate a clear line in the wells. The images of mobilized cells were captured from every well with a digital camera at 0 and 24 h post scratching for bladder cancer cells. Relative migration distance was measured using Photoshop software. To validate the scratch assay data, a transwell assay was also conducted. Approximately 10,000 transfected cells enriched with 100 µl serum-free medium were planted into the upper compartments (24-well plate, pore size 8 µm, Corning). 500 µl of DMEM medium enriched with 10% FBS was introduced into the lower compartments in each well. The cells were grown for 24 h and then the chambers were rinsed with PBS twice. Afterward, 4% paraformaldehyde fixation of the cells under the lower compartment surface was done for 30 min. Subsequently, 0.1% crystal violet staining of the cells was done for 40 min, followed by rinsing twice with PBS. An inverted microscope was employed to observe the migrated cells, which were imaged. Lastly, 600 µl of 33% glacial acetic acid was introduced to each chamber to wash out the crystal violet and was then incubated for 30 min. 100 µl of scrubbing solution was added to 96-well plates and a microplate reader was employed to examine the absorbance at 570 nm.

**Caspase 3 ELISA Assay**

Caspase 3 ELISA analysis was employed to investigate cell apoptosis. 5637 and SW780 bladder cancer cells were inserted with sg-SNHG3 or sg-NC in 12-well plates through transfection. Forty-eight hours post transfection, the activity of capase-3 was employed to assay the apoptosis caused by decreased SNHG3 expression as described in the manufacturer manual (Cusabio, Wuhan, China). Absorbance was examined by a microplate reader. The ratios between the OD values of the sg-SNHG3 cell transfects and those of the sg-NC cell transfects were employed to present the results. Experiments were replicated at least three times.

**Statistical Analyses**

All these statistical analyses were executed with SPSS 20.0. The Paired samples t-test was employed to explore the SNHG3 RNA expression differences between bladder cancer tissues and matching non-malignant tissues. Moreover, the differences in SNHG3 RNA content between cancer cells and SV-HUC1 were assessed using the independent samples t-test. The results of the CCK-8 assay and MTT assay were explored by the independent samples t-test at each time point. Cell migration along with an apoptosis assay were assessed by the independent samples t-test. P < 0.05 designated statistical significance.

**RESULTS**

**LncRNA SNHG3 Is Highly Expressed in Bladder Cancer Tissues and Cell Lines**

The relative lncRNA SNHG3 expression was determined by performing a qRT-PCR assay in bladder cancer tissues, as well as the cells. In contrast with the matching non-malignant bladder peritumoral tissues, SNHG3 expression was highly expressed in 68.3% (28 of 41) of bladder cancer tissues (Figure 1A). The SNHG3 expression fold change (bladder cancer tissues/corresponding non-malignant tissues) in total bladder cancer patients is shown in Figure 1B. Moreover, elevated SNHG3 content was strongly linked to the TNM stage along with histological grade of individuals with bladder cancer, but irrelevant to other clinical features, including gender, lymph node metastasis, age, distant metastasis, as well as tumor size (Table 1). The expression differences based on the TNM stage and histological grade were shown as follows. The SNHG3 expression fold change in T2-T4 stage bladder cancer tissues was 2.47 times compared to T1 stage.

**TABLE 1 | Relationship of SNHG3 expression with clinicopathological features of bladder cancer patients.**

| Parameters                  | Group               | Total | Expression | P-value |
|-----------------------------|---------------------|-------|------------|---------|
|                             |                     | High  | Low        |         |
| Gender                      | Male                | 26    | 16         | 10      | 0.221   |
|                            | Female              | 15    | 12         | 3       |         |
| Age (years)                 | <60                 | 10    | 6          | 4       | 0.779   |
|                            | >60                 | 31    | 22         | 9       |         |
| Tumor size                  | <3                  | 14    | 10         | 4       | 0.756   |
|                            | >3                  | 27    | 18         | 9       |         |
| TNM stage                   | Ta + Tis + T1       | 12    | 5          | 7       | 0.009   |
|                            | T2 or above         | 29    | 24         | 5       |         |
| Grade                       | Low                 | 8     | 2          | 6       | 0.003   |
|                            | High                | 33    | 32         | 7       |         |
| Lymph node metastasis       | No                  | 24    | 15         | 9       | 0.344   |
|                            | N1 or above         | 17    | 13         | 4       |         |
| Distant metastasis          | No                  | 38    | 25         | 13      | 0.22    |
|                            | Yes                 | 3     | 3          | 0       |         |

P < 0.05 signified statistical significance.

**FIGURE 2 | Knockdown of SNHG3 expression.** (A) Silencing of SNHG3 with sgRNA in 5637 cell. (B) Silencing of SNHG3 with sgRNA in SW780 cell. Data were indicated as means ± SD from three independent experiments (** denotes P < 0.01). sg: sgRNA.
FIGURE 3 | SNGH3 silencing repressed in vitro cell proliferation. (A,B) CCK-8 assay illustrated that repression of SNGH3 reduced the growth of 5637 and SW780 cells. (C,D) MTT assay illustrated that SNGH3 silencing dramatically repressed the growth of 5637 and SW780 cells. Data were indicated as means ± SD from three independent experiments (** denotes \( P < 0.01 \), * denotes \( P < 0.05 \)). sg: sgRNA.

that in Ta-T1 stage bladder cancer tissues (Figure 1C). The SNGH3 expression fold change in high grade bladder cancer tissues was 2.21 times that in low grade bladder cancer tissues (Figure 1D). Moreover, the OS (Figure 1E) and DFS (Figure 1F) in the SNGH3 overexpression group was remarkably lower in contrast to that in the SNGH3 down-regulation group, indicating that SNGH3 could be applied as a prognostic indicator for bladder cancer. Lastly, we established that SNGH3 was highly expressed in the bladder cancer cells (5637 and SW780) in contrast to that in SV-HUC1 (Figure 1G), implying that SNGH3 is a bladder cancer oncogene. Hence, 5637 and SW78O cells were selected to perform functional experiments.

Specific sgRNA Inhibited the Expression of SNGH3

According to the promoter sequence of SNGH3, we designed three different sgRNAs (sg-SNHG3-3, sg-SNHG3-2, as well as sg-SNHG3-1) targeting SNGH3 and evaluated their efficiencies in 5637 and SW780 bladder cancer cells inserted with a sg-SNHG3 or sgRNA negative control (sg-NC). At 48 h post transfection, SNGH3 expression was measured. As shown in Figures 2A,B, sg-SNHG3-1 induced the maximal knockdown effect of SNGH3 in 5637 and SW780 cells. Therefore, sg-SNHG3-1 was used to perform the functional experiments.

Suppression of SNGH3 Repressed Cell Proliferation

To assess the influence of SNGH3 on cell growth, CCK-8 assay along with MTT assay were carried out. As indicated in Figures 3A,B, the results of CCK-8 demonstrated that sg-SNHG3 repressed cell growth remarkably in both 5637 and SW780 cells. In addition, the results of MTT were congruent with the results of the CCK-8 assay data. As indicated in Figures 3C,D, SNGH3 silencing remarkably reduced the growth curve of SW780 and 5637 cells. Collectively, the data confirmed that suppression of SNGH3 inhibited bladder cancer cell growth.
SNHG3 Silencing Promoted Cell Apoptosis

Forty-eight hours post transfection, we harvested the bladder cancer cells and then used them to perform the Caspase-3 ELISA assay. As indicated in Figures 4A,B, there were remarkably elevated relative Caspase-3 activity in sg-SNHG3 bladder cancer cells in contrast with sg-NC cell transfects.

Knockdown of SNHG3 Inhibited Cell Migration and Infiltration

The scratch assay along with the transwell assay were employed to verify the effect of SNHG3 on cell migration, as well as infiltration. The scratch experiment showed that bladder cancer cells transfected with sg-SNHG3 exhibited a slower rate of closing of scratched wounds in contrast with the sg-NC groups (Figures 5A,B). Further data analysis indicated that the relative migration distance in the sg-SNHG3 group was decreased by 49% in the 5637 cell (Figure 5C) and reduced by 60% in the SW780 cell (Figure 5D). The Transwell assay was additionally conducted to explore bladder cancer cell invasion. In contrast with the sg-NC group, cell infiltration potential of the sg-SNHG3 group was extremely inhibited in the 5637 (Figure 6A) and SW780 cells (Figure 6B). The OD value of washing-up liquid in the sg-SNHG3 transfected 5637 (Figure 6C) and SW780 cells (Figure 6D) was remarkably lower in contrast with the sg-NC group. Altogether, these data revealed that SNHG3 silencing repressed migration along with the infiltration of bladder cancer cells.

DISCUSSION

LncRNAs are a kind of non-protein coding RNAs with a length of about 200 nucleotides. Mounting research evidence suggest that LncRNAs are involved with gene expression regulation by...
affecting the gene transcription, post-transcriptional process, and chromatin modification (Meller et al., 2015; Engreitz et al., 2016). Furthermore, lncRNAs can act as competitive endogenous RNA to capture microRNA which can suppress the transcriptional and translational process by docking to the 3′UTR region of mRNA (Thomson and Dinger, 2016). Hence, lncRNAs participate in modulatory roles in nearly all the biological processes, constituting cell growth, tissue, as well as organ development, cell apoptosis, energy metabolism, and so on (Kopp and Mendell, 2018; Krause, 2018). However, dysregulation of lncRNAs will cause the disorder of the internal environment and multiple types of human diseases, especially cancers. Aberrant expression of lncRNAs can enhance the growth, infiltration, and drug resistance of cancer cells. Moreover, the disorder of lncRNAs can disturb the cell apoptosis process (Parasramka et al., 2016; Schmitt and Chang, 2016). For instance, upregulation of lncRNA HOXD-AS1 has been documented in bladder cancer tissues, as well as cells, and HOXD-AS1 can enhance the cell growth and migration, but can repress cell apoptosis during the progression of bladder cancer (Li et al., 2016). LncRNA SPRY4-IT1 enhances the growth along with the metastasis of bladder cancer cells though sponging miR-101-3p to increase EZH2 expression (Li et al., 2017; Liu et al., 2017). As a recently identified lncRNA, multiple previous studies were summarized to characterize the oncogenic features of lncRNA SNHG3, a 2,238 nt in length lncRNA located on chromosome 1p36.1. SNHG3 is overexpressed in hepatocellular carcinoma (HCC) tissues in contrast with the matched non-malignant tissues. SNHG3 RNA content is positively correlated with portal vein tumor thrombus tumor size and tumor relapse of HCC patients. Increased expression of SNHG3 causes lower OS, poorer recurrence-free survival, as well as lower DFS (Zhang et al., 2016). Zhang et al. (2018) demonstrated that overexpression of SNHG3 facilitates cell infiltration, the epithelial–mesenchymal transition (EMT) progress, along with sorafenib resistance by sponging miR−128 to up-regulate CD151 expression in HCC cells. Huang et al. (2017) extracted the data from the TCGA dataset and documented that SNHG3 was up-regulated in CRC tissues and cells in contrast with neighboring non-malignant tissues and normal cells, respectively. SNHG3 silencing repressed cell growth and tumor growth by capturing miR-182-5p, which can suppress c-Myc expression. Fei et al. (2018) found that SNHG3 could recruit EZH2 to the KLF2 and p21 promoter region to suppress KLF2 and p21 expression in the malignant progression of glioma cells. Li et al. (2018) also extracted the data of ovarian cancer from the TCGA data resource and documented that SNHG3 was closely linked to the OS and energy metabolism. Further analysis suggested that SNHG3 absorbed miRNAs and EIF4AIII to affect the expression of UQCRH, IDH2, PKM, and PDHB and in the energy metabolism related cascades. Moreover, SNGH3 was remarkably overexpressed in lung adenocarcinoma samples in contrast with neighboring samples. Forced SNGH3 expression facilitated A549 cell growth and inhibited A549 cell apoptosis (Liu et al., 2018). In general, SNGH3 is overexpressed in HCC,
Cao et al. Knockdown of SNGH3 by CRISPR-dCas9

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Research Ethics Committee of the Affiliated Foshan Maternal and Child Healthcare Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YC, QH, RZ, ML, MG, HW, LZ, and JW performed the biological experiments and data analyses. CL designed and supervised the project. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Guangdong Provincial Medical Science and Technology Research Funding (No. 20205792148508), the Changsha Science and Technology Bureau project (No. kq1907033), the National Nature Science Foundation of China (No. 81703919), and the Hunan Natural Science Foundation (No. 2020JJ5418).

REFERENCES

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. doi: 10.3322/caac.21492

Chen, D., Liu, L., Wang, K., Yu, H., Wang, Y., Liu, J., et al. (2017). The role of MALAT-1 in the invasion and metastasis of gastric cancer. Sand. J. Gastroenterol. 52, 790–796. doi: 10.1080/00365521.2017.1280531

Chen, Y., Xie, H., Zou, Y., Lai, X., Ma, L., Liu, Y., et al. (2017). Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells. Mol. Biosyst. 13, 1597–1607. doi: 10.1039/c7mb00202e

Chen, Y., Zhao, F., Cui, D., Jiang, R., Chen, J., Huang, Q., et al. (2018). HOXD-AS1/miR-130a sponge regulates glioma development by targeting E2F8. Int. J. Cancer 142, 2131–2132. doi: 10.1002/ijc.31362

Dy, G. W., Gore, J. L., Forouzanfar, M. H., Naghavi, M., and Fitzmaurice, C. (2017). Global Burden of Urologic Cancers, 1990-2013. Eur. Urol. 71, 437–446. doi: 10.1016/j.eururo.2016.10.008

Engreitz, J. M., Ollikainen, N., and Guttmann, M. (2016). Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat. Rev. Mol. Cell Biol. 17, 756–770. doi: 10.1038/nrm.2016.126

Evans, J. R., Feng, F. Y., and Chinnaiyan, A. M. (2016). The bright side of dark matter: IncRNAs in cancer. J. Clin. Invest. 126, 2773–2782. doi: 10.1172/JCI84421

Fei, F., He, Y., He, S., He, Z., Wang, Y., Wu, G., et al. (2018). LncRNA SNHG3 enhances the malignant progress of glioma through silencing KLF2 and p21. Biosci. Rep. 38:BSR20180420.
Li, J., Chen, Y., Chen, Z., He, A., Xie, H., Zhang, Q., et al. (2017). SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers. Tumour Biol. 39:1010428317711406.

Li, J., Zhuang, C., Liu, Y., Chen, Y., Chen, Z., et al. (2016). Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer. J. Exp. Clin. Cancer Res. 35:99.

Li, N., Zhan, X., and Zhan, X. (2018). The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes. Gynecol. Oncol. 150, 343–354. doi: 10.1016/j.ygyno.2018.06.013

Liu, D., Li, Y., Luo, G., Xiao, X., Tao, D., Wu, X., et al. (2017). LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Lett. 388, 281–291. doi: 10.1016/j.canlet.2016.12.005

Liu, L., Ni, J., and He, X. (2018). Upregulation of the Long Noncoding RNA SNHG3 Promotes Lung Adenocarcinoma Proliferation. Dis. Markers 2018:5736716.

Marchese, F. P., Raimondi, I., and Huarte, M. (2017). The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 18:206.

Massari, F., Santoni, M., di Nunno, V., Cheng, L., Lopez-Beltran, A., Cimadamore, A., et al. (2018). Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treat. Rev. 68, 80–85. doi: 10.1016/j.ctrv.2018.06.002

Meller, V. H., Joshi, S. S., and Deshpande, N. (2015). Modulation of Chromatin by Noncoding RNA. Annu. Rev. Genet. 49, 673–695. doi: 10.1146/annurev-genet-112414-053205

Milevskiy, M. J., Al-Ejeh, F., Saunus, J. M., Northwood, K. S., Bailey, P. J., Betts, J. A., et al. (2016). Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer. Hum. Mol. Genet. 25, 3269–3283.

Parasramka, M. A., Maiti, S., Matsuda, A., Yan, I. K., and Patel, T. (2016). Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol. Ther. 161, 67–78.

Ponting, C. P., Oliver, P. L., and Reik, W. (2009). Evolution and functions of long noncoding RNAs. Cell 136, 629–641.

Portoso, M., Ragazzini, R., Brincic, Z., Moiani, A., Michaud, A., Vassilev, I., et al. (2017). PRC2 is dispensable for HOTAIR-mediated transcriptional repression. EMBO J. 36, 981–994.

Quinodoz, S., and Guttman, M. (2014). Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. Trends Cell Biol. 24, 651–663.

Schmitt, A. M., and Chang, H. Y. (2016). Long Noncoding RNAs in Cancer Pathways. Cancer Cell 29, 452–463.

Shan, Y., Ma, J., Pan, Y., Hu, J., Liu, B., and Jia, L. (2018). LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1. Cell Death Dis. 9:722.

Sun, Y., Wei, G., Luo, H., Wu, W., Skogerbo, G., Luo, J., et al. (2017). The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes. Oncogene 36, 6774–6783.

Thomson, D. W., and Dinger, M. E. (2016). Endogenous microRNA sponges: evidence and controversy. Nat. Rev. Genet. 17, 272–283.

Tsai, M. C., Manor, O., Wan, Y., Mosammaparast, N., Wang, J. K., Lan, F., et al. (2010). Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689–693.

Vigouroux, A., Oldewurtel, E., Cui, L., Bikard, D., and van Teeffelen, S. (2018). Tuning dCas9\’s ability to block transcription enables robust, noiseless knockdown of bacterial genes. Mol. Syst. Biol. 14:e8799.

Wu, C., Zhu, X., Tao, K., Liu, W., Ruan, T., Wan, W., et al. (2018). MALAT1 promotes the colorectal cancer malignancy by increasing DCP1A expression and miR203 downregulation. Mol. Carcinog. 57, 1421–1431.

Zhang, P. F., Wang, F., Wu, J., Wu, Y., Huang, W., Liu, D., et al. (2018). LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. J. Cell Physiol. 234, 2788–2794.

Zhang, T., Cao, C., Wu, D., and Liu, L. (2016). SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma. Tumour Biol. 37, 2379–2385.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Cao, Hu, Zhang, Li, Guo, Wei, Zhang, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.